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Abstract
Connexins have been frequently identified as tumor suppressors in many cancers, however,
their role in melanoma tumorigenesis remains controversial. Here, we show that B16-BL6
mouse melanoma cells express low levels of Cx26 and Cx43, rendering them gap junctional
intercellular communication (GJIC) deficient. Following ectopic expression of Cx26 and
Cx43, gap junction-like plaques were evident at the cell surface and the incidence of dye
transfer was significantly increased similar to connexin-rich keratinocytes. The expression of
Cx43, but not Cx26, significantly reduced proliferation and anchorage-independent growth
relative to controls, whereas migration was unaffected.

Additionally, Cx43-expressing

melanoma cells displayed significantly reduced growth amongst keratinocytes, despite a
complete lack of heterocellular GJIC. Furthermore, when grown in vivo in the chicken
embryo, Cx43-expressing melanoma cells formed significantly smaller primary tumors
compared to controls, whereas Cx26 expression did not alter primary tumor size.
Collectively, these results suggest that Cx43, but not Cx26, acts as a tumor suppressor during
melanoma tumorigenesis.
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Chapter 1

1

Literature Review

1.1 Connexins and Gap Junctions
Connexins (Cx) encompass a large family of integral membrane proteins that are
expressed across all vertebrates. To date, 21 distinct connexins have been identified in
the human genome and 20 connexins are expressed in rodents (Sohl and Willecke, 2003).
Interestingly, of these connexins, 19 are homologous and highly conserved, allowing for
functional insights on one connexin to be extended to other connexin family members
and across different species (Sohl and Willecke, 2004). Although the lifecycle for each
connexin family member has not been studied in depth, the well-characterized lifecycle
for Cx43 often serves as a model for other connexins. Cx43 is co-translationally inserted
into the endoplasmic reticulum as a tetra-membrane spanning protein, which creates
several distinct domains, including two extracellular loops, one cytoplasmic loop, and
cytoplasmic amino- and carboxy-terminal tails. Once properly folded, Cx43 is trafficked
to the Golgi apparatus, where individual connexin proteins oligomerize into a hexameric
arrangement, known as a connexon.

Following oligomerization, connexons are

subsequently trafficked to the cell surface where they can function as single-membrane
‘hemichannels’ permitting the passage of small molecules between the intracellular and
extracellular environment. Additionally, these connexin hemichannels possess the ability
to dock with compatible connexons from apposing cells forming gap junction channels,
thereby permitting the passage of small molecules, second messengers and ions between
apposing cells (Fig. 1.1A) (Laird, 2006). Although the majority of gap junctions are
composed of identical connexin subunits, non-identical connexins can oligomerize into
heteromeric connexons and form functional gap junctions (Fig. 1.1A) (Wagner, 2008).
For example, Cx26 and Cx32 are known to intermix in hepatocytes while Cx46 and Cx50
co-oligomerize in the lens (Jiang and Goodenough, 1996; Sosinsky, 1995). To add to this
complexity, non-identical connexons may also dock at cell-cell interfaces, forming
heterotypic gap junction channels, which greatly increases the variety of distinct gap
junction channels that can form (Fig. 1.1A) (Wagner, 2008). However, not all connexins
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Figure 1.1

Connexin topology and organization into gap junction channels

Connexins oligomerize into hexamers, known as connexons, and dock with connexons
from opposing cells to form gap junction channels. Typically, homomeric connexons
form from one connexin isoform and dock with an identical connexon into a homotypic
gap junction channel. However, non-identical connexons can dock forming heterotypic
gap junction channels, and similarly, non-identical connexins can oligomerize into
heteromeric connexons (A). All connexins share a similar topology, composed of four
transmembrane domains (M1-M4), two extracellular loops (EL1 and EL2), an
intracellular loop (IL) and intracellular amino-terminal (NH2) and carboxy-terminal
(COOH) tails. The transmembrane domains, extracellular loops and amino-terminal tails
are highly conserved across connexin family members. Conversely, the intracellular loop
and carboxy-terminal tails are the most diverse domains between connexins, both in
amino acid sequence and length (B).
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are compatible with each other and capable of oligomerizing into mixed connexons, and
similarly, not all connexons are capable of docking and forming heterotypic gap junction
channels. For example, when expressed in the same cell, Cx26 and Cx43 are incapable
of intermixing (Gemel et al., 2004). Although connexins have been divided into two
broad subgroups (denoted as alpha and beta groups) which is generally based on size,
there does not appear to be an obvious criteria to predict connexin compatibility (White
and Bruzzone, 1996).
All connexins share a common topology, including four transmembrane domains, two
extracellular loops, one intracellular loop, and intracellular amino- and carboxy-terminal
tails (Fig. 1.1B) (Goodenough et al., 1996).

Of these regions, the transmembrane

domains, extracellular loops and amino-terminal tail are highly conserved across
connexin family members (Sohl and Willecke, 2004). Specifically in the extracellular
loops, three highly conserved cysteine residues exist allowing for stabilizing
intramolecular disulfide linkages (John and Revel, 1991). Conversely, the carboxyterminal tail is the most diverse region across connexin family members, not only in
sequence, but also in length (Laird, 2006). Some connexins possess phosphorylation
sites within the carboxy-terminus that have been reported to regulate the connexin life
cycle and channel permeability (Lampe and Lau, 2004).

1.2 Gap Junctions and Intercellular Communication
The ability to transfer small molecules, second messengers and ions between cells
through gap junctions (known as gap junctional intercellular communication, or GJIC) is
essential for the regulation of many cellular processes including proliferation,
differentiation and apoptosis (Goodenough et al., 1996). Although the exact knowledge
of which molecules are passing through gap junctions in any given tissue remains mostly
unknown, for a few connexins, some work has been done on the identity of these
transjunctional molecules and their relative permeabilities.

The second messengers

inositol-1,4,5-triphosphate (IP3) and cyclic adenosine monophosphate (cAMP) have been
extensively studied and have been shown to pass though gap junctions consisting of
Cx26, Cx26/Cx30, Cx26/Cx32, Cx32, Cx43 and Cx26, Cx32, Cx36, Cx43, Cx43/Cx46,
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Cx45, Cx47, respectively (Harris, 2007). Calcium ions have been shown to pass through
Cx26, Cx32, Cx37, Cx37/Cx43 and Cx43 gap junction channels, whereas adenosine
diphosphate (ADP)/adenosine triphosphate (ATP) has only been shown to pass though
channels consisting of Cx32 and Cx43 (Alexander and Goldberg, 2003; Harris, 2007). It
is important to note that although gap junction channels composed of different connexins
possess the ability to pass many of the same constituents, the relative permeabilities of
these channels is distinct for each molecule (Harris, 2007). For example, IP3 has been
shown to pass through various gap junction channels, but it appears to preferentially pass
through Cx32-based channels compared to channels consisting of Cx43, which in turn is
more permeable than Cx26-based gap junction channels (Harris, 2007). It was initially
postulated that pore size and molecular charge may dictate the passage of molecules
through distinct gap junctions, however, this generalization was later shown to be false
(Harris, 2007). For example, adenosine passes through Cx32 channels 10-fold better than
Cx43 channels, but adenosine with the addition of one, two, or three phosphate groups
(resulting in AMP, ADP and ATP, respectively) exhibits a shift in permeability favoring
passage through Cx43-based gap junction channels (Alexander and Goldberg, 2003).

1.3 GJIC-Independent Roles for Connexins
Although the ability to form gap junctions allowing for the transfer of molecules between
apposing cells is commonly believed to be the primary function of connexins, these
proteins also possess GJIC-independent roles.

Once at the cell surface, connexons

typically dock forming gap junction channels, however, connexons have been reported to
act as single membrane hemichannels exchanging molecules with the extracellular
environment (Wang et al., 2013).

Hemichannels are typically closed under normal

physiological conditions, but can be opened due to several stimuli including voltage
changes, extracellular and intracellular ion changes, mechanical strain and posttranslation modifications (Wang et al., 2013). Similar to their gap junction counterparts,
the identity of molecules able to pass through hemichannels remains limited to small
molecules, but includes ATP, IP3, cAMP, nicotinamide adenine dinucleotide (NAD+),
glutamate, glutathione and prostaglandin E2 (PGE2) (Harris, 2007; Wang et al., 2013).
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In addition to the formation of undocked hemichannels, connexins may also affect
cellular physiology through direct connexin binding partners and indirect interactions as
part of a junctional complex. Connexins have been reported to bind to various posttranslational modifiers involved in phosphorylation (Solan and Lampe, 2009), scaffolding
and cytoskeletal proteins including various zonula occludens (ZO) and ZO-binding
proteins (Gilleron et al., 2008; Hunter et al., 2005), trafficking proteins necessary for
delivery to the cell surface and internalization, including caveolin proteins (Langlois et
al., 2008) and other growth regulators including nephroblastoma overexpressed protein
(NOV or CCN3) (Fu et al., 2004). It should be noted, however, that this collective gap
junction proteome, which now includes over 40 distinct proteins, appears to be connexinspecific (Laird, 2010). Each connexin family member possesses a unique subset of this
proteome, which may in large part be due to difference amongst connexin isoforms,
primarily within the carboxy-terminal domain (Fig. 1.1B) (Laird, 2010; Naus and Laird,
2010). For example, Cx43 has 14 known serine and tyrosine phosphorylation sites on its
large carboxy-terminus (Lampe and Lau, 2004), whereas Cx26 has not been reported to
be phosphorylated (Traub et al., 1989).

1.4 Cells of the Epidermis
The epidermis covers the outermost layer of the human body as the most superficial layer
of the skin and acts as a physical barrier to environmental stresses (Cartlidge, 2000).
Keratinocytes make up the vast majority of the epidermis, and are divided into five
epidermal strata. A single layer of basal keratinocytes, which rests atop a basement
membrane separating the epidermis from the underlying dermis, is the deepest of the
epidermal layers and acts as the site for epidermal stem and progenitor cells which can
proliferate and replenish keratinocytes in the layers above (Eckert et al., 1997). These
basal keratinocytes differentiate sequentially to form the stratum spinosum, stratum
granulosum and stratum lucidum, collectively termed the suprabasal layers, before finally
undergoing apoptosis to form the stratum corneum (Fig. 1.2) (Eckert et al., 1997).
The second most abundant cell type of the epidermis is the melanocyte. Melanocytes
reside in the basal layer of the epidermis and typically form the ‘epidermal-melanin unit’,
where one melanocyte forms connections with approximately 30 keratinocytes within the
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Figure 1.2

Connexins involved in the epidermal-melanin unit

Melanocytes, which reside in the basal layer of the epidermis, extend their dendrites into
the suprabasal layers and form connections with approximately 30 keratinocytes.
Through their expression of Cx43 and Cx26, melanocytes are believed to be capable of
GJIC with basal and suprabasal keratinocytes, respectively, which helps to maintain the
epidermal-melanin unit. Cx43 is highly expressed amongst basal keratinocytes and also
found within the stratum spinosum. Conversely, Cx26 appears to be confined to the
stratum granulosum. Additionally, suprabasal keratinocytes express Cx30, Cx31, Cx37,
Cx40 and Cx45 (not shown in figure).
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basal and suprabasal layers (Fig. 1.2) (Haass and Herlyn, 2005). Melanocytes are vital to
the epidermis and underlying tissues due to their production and release of the pigment
melanin which protects cells from ultraviolet (UV) radiation damage (Lin and Fisher,
2007).

Epidermal melanocytes produce two types of melanin; pheomelanin and

eumelanin, which are transported to surrounding keratinocytes through dendritic
processes and released via exocytosis. These pigment-containing granules, known as
melanosomes, are ingested by keratinocytes where they form protective ‘caps’ above the
nucleus to prevent DNA damage from UV radiation (Lin and Fisher, 2007).
Interestingly, melanocytes tend to maintain a symbiotic relationship with keratinocytes,
exhibiting controlled replication such that they maintain a ratio of approximately 1:5-8
with basal keratinocytes (Hsu et al., 2000b). It is commonly believed that melanocyte
growth and proliferation is controlled by these surrounding keratinocytes through various
mechanisms including paracrine signaling, intercellular communication and intracellular
communication (Haass et al., 2004).
Although keratinocytes and melanocytes account for nearly all cells within the epidermis,
two additional cell types are found in this tissue. Merkel cells reside within the stratum
basale, acting as sensory receptors to light touch through synaptic connections with
somatosensory neurons (Maricich et al., 2009).

Additionally, Langerhans cells are

present within the suprabasal layers. These dendritic cells possess immune function and
act as antigen-presenting cells when exposed to foreign microbial agents (Wolff and
Stingl, 1983).

1.5 Connexins Expressed within the Epidermis
The epidermis is one of the most diverse connexin environments across all mammals. In
human epidermis, as many as 10 connexins are expressed at the messenger ribonucleic
acid (mRNA) level, with 7 of these being translated into detectable levels of proteins,
primarily within epidermal keratinocytes. Interestingly, these connexins are differentially
regulated across the different epidermal strata. Cx43 is highly expressed in the stratum
basale as well as trace levels of Cx26. As many as 7 connexins are expressed in the
suprabasal layers, including Cx26, Cx30 Cx31, Cx37, Cx40, Cx43 and Cx45, although
Cx26 appears to be confined to the stratum granulosum (Di et al., 2001; Richard, 2000).
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Similarly, in rodent epidermis, Cx31.1, Cx40 and Cx43 are expressed in the basal layer,
Cx31.1, Cx37, Cx43 are expressed in the stratum spinosum, and Cx31, Cx37, Cx26 and
Cx30 are expressed in cells within the stratum granulosum (Churko and Laird, 2013).
Across all mammals, the cornified layer is devoid of connexins, as this stratum contains
no living cells. Overall, the selective and spatial specific expression of connexins within
the epidermis is vital to proper development, proliferation and differentiation of the
epidermis (Richard, 2000).
In contrast to keratinocytes, the connexins status of melanocytes has been much less
studied.

Two studies suggest that Cx26 and Cx43 are the predominant connexins

expressed in human melanocytes (Hsu et al., 2000a; Masuda et al., 2001), while
connexins have yet to be reported in rodent melanocytes. Additionally, Cx32 has also
been implicated in melanocyte biology, although the evidence for a role for Cx32 is not
strong (Bondurand et al., 2001).

Importantly, melanocytes have been shown to be

capable of GJIC with keratinocytes, possibly through channel formation with
complementary connexins in both cell types (Fig. 1.2) (Hsu et al., 2000a). It has been
proposed that melanocyte growth and proliferation is, in part, mediated by this
heterocellular GJIC with keratinocytes (Fig. 1.2) (Haass et al., 2004).
A very limited amount of work has been done on the connexin profile in Merkel cells and
Langerhans cells. Woo et al. (2010) have shown that mouse Merkel cells express Cx43.
Conversely, connexins have not been reported in Langerhans cells.

Goliger and Paul

(1994) showed that rat Langerhans cells do not couple with adjacent keratinocytes
through dye transfer studies, which was later supported in human Langerhans cells
(Zimmerli et al., 2007).

1.6 Cancers Derived from the Epidermis
Several cancers can arise within the epidermis depending on the lineage of the initial
transformed cell. In general, epidermal skin cancers can be classified as either nonmelanoma skin cancer (NMSC) or melanoma skin cancer (Gallagher et al., 1990). Nonmelanoma skin cancers are derived from keratinocytes, and can be further subdivided
into two groups depending on the subclass of keratinocyte that becomes transformed.
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Basal cell carcinomas (BCC) are cancers derived from basal keratinocytes and account
for the vast majority of reported skin cancers (Christenson et al., 2005). These cancers
are typically found on areas of high sun exposure, primarily the head and neck, and are
generally believed to be benign, metastasizing less than 0.1% of the time (Netscher et al.,
2011). Squamous cell carcinomas (SCC) are derived from suprabasal keratinocytes and
are more aggressive than BCCs as they can metastasize due to malignant precursors,
potentially depending on in situ subtypes (Netscher et al., 2011). Melanoma skin cancers
are derived from pigment-producing melanocytes, and are the result of the vast majority
of skin cancer-related fatalities (Miller and Mihm, 2006). In addition to these two classes
of epidermal skin cancers, Merkel cells have also been recently discovered to form
tumors within the epidermis, although Merkel cell carcinomas (MCC) are classified as
neuroectodermal tumors (Feng et al., 2008). Similar to melanomas, MCCs are highly
aggressive with an overall 5-year survival rate of ~60% (Schrama et al., 2012).

1.7 Melanoma as a Disease
Although melanoma only accounts for ~4% of reported skin cancers, it remains the most
lethal form of skin cancer accounting for ~80% of skin cancer-related fatalities as of 2004
(Tsao et al., 2004). In fact, the global incidence of melanoma appears to be continually
increasing, and has been consistently doing so for over 60 years (Linos et al., 2009).
Primarily, the high mortality rate that accompanies melanoma is the result of a high
incidence of metastasis to the liver, brain, lung and bone, which can significantly
decrease the survival rate to as low as 7%, compared to a 99.9% survival rate when
identified early in situ within the epidermis (Balch et al., 2001a; Miller and Mihm, 2006).
Melanomas are typically identified within the epidermis as pigmented lesions. As a
general rule of thumb to predict severity, clinicians use the mnemonic “ABCDE”.
Lesions with Asymmetrical borders, irregular Borders, variegated Colours, Diameter of
>6mm, and that are continuously Evolving over time are characterized as potential
melanomas and are usually removed and analyzed (Netscher et al., 2011).
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1.8 Melanocyte Transformation and Melanoma Progression
The symbiotic relationship between melanocytes and keratinocytes is defined as the
epidermal-melanin unit, where one melanocyte forms connections with approximately 30
keratinocytes (Haass and Herlyn, 2005). The association with keratinocytes through the
formation of the epidermal-melanin unit causes melanocytes to become dendritic,
suppress melanoma-associate cell surface markers and control melanocyte proliferation
(Valyi-Nagy et al., 1993). Melanocyte transformation disrupts the epidermal-melanin
unit, thereby freeing melanocytes from the control of keratinocytes and facilitates the
progression towards malignant melanoma (Miller and Mihm, 2006).

The Clark

progression model remains one of the most commonly used staging classifications for
melanoma progression.

This model tracks the transformation of melanocytes to

precancerous nevi through to radial and vertical growth phases of the melanoma, and
finally to the metastatic stage of the melanoma (Clark et al., 1984).
The development of a benign nevus, or common mole, initiates the dissociation of
melanocytes from the control of keratinocytes and exhibits partially disrupted growth and
proliferation (Clark et al., 1984). This proliferation, however, remains limited and does
not lead to immediate tumorigenesis, likely due to oncogene-induced senescence (Braig
and Schmitt, 2006), and further transformation is required to progress the nevus towards
a more malignant phenotype (Miller and Mihm, 2006). For example, BRAF mutations
are associated with 50% of melanomas, however, this frequency appears to be similar
between benign nevi, primary, and metastatic melanoma, suggesting other combinatorial
mutations, such as inactivating p53, are necessary to further the disease (Michaloglou et
al., 2005; Pollock et al., 2003). Dysplastic nevi can form from pre-existing benign nevi
or arise as new lesions and exhibit further aberrant growth. Additional mutations may
accumulate at this stage, including to the tumor suppressor phosphatase and tensin
homolog gene (PTEN), which occurs in 25-50% of non-familial melanomas (Wu et al.,
2003). Inactivation of PTEN alone is not sufficient to cause melanoma, however, when
combined with mutations to the cyclin-dependent kinase inhibitor 2A gene (CDKN2A),
which occurs in 25-40% of familial melanomas, tumors can arise (Thompson et al., 2005;
You et al., 2002). Collectively, it is understood that no singular mutation results in
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melanoma tumorigenesis, but rather, a collection of detrimental mutations are necessary
to further the disease.
The next stage of melanoma tumorigenesis, as proposed by Clark et al. (1984), occurs as
radial growth phase melanoma.

Here, melanoma cells display further increased

proliferation, however, they only proliferate within the confines of the epidermis as they
lack the ability to penetrate through the epidermal basement membrane and into the
underlying dermis (Miller and Mihm, 2006). The ability of melanomas to penetrate the
basement membrane and invade the dermis, thereby entering the vertical growth phase, is
accompanied by the expression of αvβ3 integrin, resulting in the induction of matrix
metalloproteinase-2 (MMP-2); an enzyme necessary to weaken the basement membrane
(Brooks et al., 1996; Danen et al., 1994). Transition from radial to vertical growth phase
is also accompanied by a concomitant shift in expression from E-cadherin to N-cadherin
(Danen et al., 1996; Hsu et al., 1996). This ‘cadherin shift’ is commonly associated with
invasive carcinomas of epithelial origin, and allows for further spread of the disease by
associating with other N-cadherin-expressing cells, including fibroblasts and endothelial
cells (Hazan et al., 2004; Hsu et al., 2000a). The absolute depth, spread and progression
of melanoma is often further characterized using the Breslow index which is the best
method for predicting prognosis for melanoma lesions in the skin (Balch et al., 2001b).
Once melanoma cells have entered the vertical growth phase and spread into the dermis,
melanoma cells can acquire metastatic potential, which has been correlated with
decreased expression of the transient receptor potential cation channel subfamily M
member 1 (TRPM1) (Miller et al., 2004). Metastatic melanomas primarily spread to the
liver, bone, brain and lungs which greatly worsens overall prognosis (Miller and Mihm,
2006).

1.9 Current Therapeutic Targets for
Melanoma/Personalized Medicine
Currently, very few therapies and therapeutic targets exist to treat advanced melanoma,
which is part of the reason this cancer remains so lethal. Activating BRAF mutations
have been associated with 50% of melanomas, which cause constitutive activation of the
extracellular signal-regulated kinase (ERK) - mitogen-activated protein kinase (MAPK)
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pathway resulting in melanoma growth (Miller and Mihm, 2006). Because of this, small
molecules have been designed to target BRAF, however, these were met with limited
success in the clinic (Lyons et al., 2001). Additionally, the growth of BRAF-mutated
melanomas can be suppressed through the inhibition of mitogen-activated protein kinase
kinase (MEK), an enzyme downstream of BRAF, making MEK a suitable therapeutic
target (Solit et al., 2006), and is currently undergoing clinical investigation. Furthermore,
genomic analysis using a database of melanoma samples found that the microphthalmiaassociated transcription factor (MITF) locus frequently displays increased copy number
leading its increased protein expression (Garraway et al., 2005). Although increased
MITF expression alone has not been reported to transform melanocytes, melanoma can
arise as a result of increased MITF and BRAF. Given this, MITF has been identified as
another potential therapeutic target in the ERK-MAPK pathway for individuals harboring
activating BRAF mutations (Garraway et al., 2005). Due to the limited identification of
therapeutic targets for melanoma, it is imperative to identify new targets with the hopes
of bettering the bleak prognosis for melanoma patients with advanced disease. In our
study, we assessed the role of two connexins, Cx26 and Cx43, in melanoma
tumorigenesis with the goal of elucidating new therapeutic targets.

1.10 Connexins in Cancer
The exchange of molecules between cells through GJIC has been implicated in cancer for
nearly 50 years (Loewenstein and Kanno, 1966).

Primarily, connexins have been

implicated as tumor suppressors in many cancers due to the fact that they are frequently
downregulated in tumor cell lines and histological sections of solid tumors in mammals
(Cronier et al., 2009; Laird et al., 1999; Loewenstein and Kanno, 1966; Mesnil et al.,
2005). Additionally, connexin-knockdown studies, gap junction blockers which promote
tumorigenesis, and oncogenes which reduce gap junction permeability or connexin
expression further support the notion that connexins act as tumor suppressors (Atkinson
et al., 1981; Azarnia and Loewenstein, 1984a; Azarnia and Loewenstein, 1984b; Azarnia
and Loewenstein, 1984c; Trosko et al., 1990). However, perhaps the most compelling
evidence that connexins have tumor suppressive capabilities lie in the findings that
ectopically reintroducing connexins into tumor cell lines reduces their tumorigenic
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behavior and connexin-knockout mice are more prone to developing chemically- and
radiation-induced tumors (Eghbali et al., 1991; Hellmann et al., 1999; Hirschi et al.,
1996; King and Lampe, 2004a; King and Lampe, 2004b; Loewenstein and Rose, 1992;
McLachlan et al., 2006; Temme et al., 1997; Zhu et al., 1991). Connexins may act as
tumor suppressors via GJIC-dependent mechanisms through the passage of
transjunctional molecules, or through GJIC-independent mechanisms, including tumor
suppressive connexin binding partners within the large gap junction proteome (Laird,
2010; Naus and Laird, 2010).

However, to think all connexins can act as tumor

suppressors across all cancers may be naïve, not only due to the various types of cancer,
but also due to the different stages of tumorigenesis where connexins may play a role. In
fact, recent evidence has shown that connexins may actually facilitate the later stages of
tumorigenesis, including extravasation and metastasis (Ezumi et al., 2008; Ito et al.,
2000; Naoi et al., 2007; Pollmann et al., 2005; Saito-Katsuragi et al., 2007; Stoletov et
al., 2013), leading to their reclassification in breast cancer as ‘conditional tumor
suppressors’ (Naus and Laird, 2010).

1.11 Connexins in Human and Mouse Melanomas
Although connexins have been implicated as tumor suppressors in many types of cancers,
the role of connexins in melanoma tumorigenesis, and their status during tumor onset and
progression remains controversial and poorly understood. In human melanoma biopsies,
Cx26 and Cx43 have been inconsistently detected. Cx26 has been shown to be expressed
in melanomas residing within the epidermis (Ito et al., 2000), and has also been reported
to be upregulated in melanomas that invade the dermis (Ito et al., 2000; Saito-Katsuragi
et al., 2007). Additionally, using the Oncomine database, Stoletov et al. (2013) reported
that increased Cx26 expression within primary melanomas correlates to increased
metastasis and poor prognosis, and others have detected ~65% of metastatic lesions
expressing Cx26 (Saito-Katsuragi et al., 2007). Conversely, Saito-Katsuragi et al. (2007)
and others did not report any Cx26 expression in melanomas in situ within the epidermis,
when assessing primary and metastatic melanomas (Haass et al., 2004; Haass et al., 2006;
Sargen et al., 2013). Similar to the discrepancies of Cx26 expression in melanomas, the
expression of Cx43 at various stages of melanoma tumorigenesis remains controversial,
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as some show its expression increases as tumorigenesis progresses (Rezze et al., 2011;
Sargen et al., 2013), whereas others do not observe its expression across various stages of
melanoma (Haass et al., 2004; Haass et al., 2006).
Limited work has been done assessing the status of connexins in human melanoma cell
lines and their role during tumorigenesis, and similar to the mixed results obtained from
human melanoma biopsies, a consensus has yet to be reached. Saito-Katsuragi et al.
(2007) showed that human HMY-1 melanoma cells express Cx26 which renders them
GJIC-competent with endothelial cells which share similar connexin and cadherin
complements. The expression of Cx26 was believed to facilitate tumor cell extravasation
and promote a more malignant phenotype. Similarly, Hsu et al. (2000a) showed at least
basal levels of Cx43 expression across various primary (WM115) and metastatic
(WM164 and 1205Lu) melanoma cells which allowed them to exhibit GJIC between
themselves and fibroblasts which also express comparable connexins and cadherins.
Conversely, some have suggested that Cx43 expression decreases throughout melanoma
tumorigenesis. Bagnato et al. (2004) showed that Cx43 and GJIC decreases in cutaneous
(1007) and metastatic (SK-Mel28, M10 and Mel120) melanoma cells due to increased
endothelin signaling through endothelin receptor B (ETRB). Additionally, it has been
reported that the Cx43 locus, located on chromosome 6, is frequently altered causing
reduced connexin expression, as found in the malignant and genetically-linked UACC903
and SRS3 melanoma cell lines (Su et al., 2000; Trent et al., 1990).
Fewer studies have assessed the status of connexins in mouse melanoma models which
can serve to provide insights into melanoma tumorigenesis. Primarily, these studies
utilized cells derived from the melanoma B16 parental cell line, which can be subdivided
into 4 isogenic lines; F0, F1, F10 and BL6, which are characterized by increasing cell
aggressiveness in vivo (Nakamura et al., 2002). Ito et al. (2000) showed that Cx26
progressively increases from F10 to BL6 melanoma cells. They reciprocally show that
functional Cx26 mediates an aggressive phenotype in F10 melanoma cells and a
dominant-negative Cx26 mutant decreases metastasis in BL6 cells.

The metastatic

phenotype of Cx26-expressing F10 and BL6 melanoma cells was attributed to an increase
in GJIC with endothelial cells. Similarly, Stoletov et al. (2013) showed that metastatic
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B16 cells also express Cx26, rendering them capable of heterocellular GJIC with
endothelial cells. Although Cx43 has been detected in human melanomas, both of these
studies did not report the expression of this connexin isoform in B16 melanoma cells, nor
did they assess the potential role of Cx43 in melanoma tumorigenesis. In our studies, we
utilize the aggressive BL6 melanoma cell line to assess the role of Cx26 and Cx43. It is
possible that each connexin may behave differently during the different stages of
tumorigenesis, and similarly, Cx26 and Cx43 may have opposing effects within the same
stage of tumorigenesis.
Several groups have assessed the effects of ectopic connexin expression or connexin
downregulation within model melanoma cell lines. Interestingly, it has been reported that
chromosome 6 is frequently altered in malignant human melanoma, including deletions to
the long arm, 6q, containing the GJA1 locus encoding Cx43 (Su et al., 2000; Trent et al.,
1990). Although the coding region of Cx43 harbors no mutations in UACC903 cells,
mutations were detected in the 3’ untranslated region (UTR), which reduced Cx43
expression (Su et al., 2000).

Ectopically expressed Cx43 significantly reduced

anchorage-independent growth of these cells, similar to the UACC903(+6) microcell
hybrid which harbors a normal chromosome 6 (Su et al., 2000). Conversely, Ito et al.
(2000) demonstrated that Cx26 facilitates metastasis in mouse melanoma cells. When
F10 melanoma cells were engineered to express Cx26, metastasis increased similar to
Cx26-expressing BL6 melanoma cells.

Similarly, when the Cx26 function of BL6

melanoma cells was abrogated via the expression of a dominant-negative Cx26 mutant,
metastasis was reduced. Given this, it is possible that Cx26 and Cx43 act differently
during melanoma tumorigenesis, thus it is important to study these connexins
individually in a unifying model.
It is maybe not surprising that the role of connexins in melanoma tumorigenesis is
unclear and complicated when we consider the complexity of cancer. It is possible that
connexins may act differently throughout the stages of tumorigenesis, potentially acting
as conditional tumor suppressors, as seems to be the case in breast cancer (Naus and
Laird, 2010). In melanoma, the majority of data implicating Cx26 in tumorigenesis
would suggest a role for this connexin as a facilitator of metastasis though the interaction
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with endothelial cells. However, Cx43 may have a tumor suppressive role in human
melanomas. Due to these differences, it is imperative to study both connexins together to
assess their role throughout the different stages of melanoma tumorigenesis.

1.12 Assessing Melanomas in Complex Environments
It is important to assess tumorigenesis in multicellular, complex systems as the tumor
microenvironment often plays a crucial role in cancer progression (Allinen et al., 2004).
This concept is further emphasized when studying the role of connexins in tumorigenesis.
Tumor cells in isolation may transmit signals via GJIC that are drastically different than
the intercellular signals transmitted when grown in mixed cell cultures or tissue settings.
Furthermore, growing tumor cells in multicellular environments allows for potential
heterocellular GJIC with surrounding untransformed cell types. A few investigators have
assessed GJIC in melanoma cells when co-cultured with keratinocytes (Hsu et al., 2000a;
Hsu et al., 2000b) as well as fibroblasts and endothelial cells (Hsu et al., 2000a; Ito et al.,
2000; Saito-Katsuragi et al., 2007; Stoletov et al., 2013). Collectively, these studies show
that melanoma cells exhibit GJIC with fibroblasts and endothelial cells, mediated through
Cx43 and Cx26, respectively.

Alternatively, melanoma cells were incapable of

heterocellular GJIC with keratinocytes, perhaps due to reduced or absent Cx43
expression. In the present study, we used a co-culture model where melanoma cells were
cultured with rat epidermal keratinocytes (REK) in an attempt to mimic the in situ
microenvironment in order to assess the effects of ectopic Cx26 and Cx43 expression in
melanoma cells on heterocellular GJIC with keratinocytes and tumor cell growth.
Although it is important to assess the phenotype of tumor cells in vitro and within in situlike models, ultimately one must implement in vivo models to assess tumorigenicity.
Only two groups have examined the role of connexins in melanoma tumor formation and
metastasis in vivo. Using immunodeficient mice, Ito et al. (2000) showed that Cx26transfected F10 and Cx26-expressing BL6 mouse melanoma cells exhibited increased
metastasis to the lung. Similarly, Cx26-expressing B16 mouse melanoma cells were
found to be more capable of colonizing the brain compared to GJIC-deficient cells
blocked with carbenoxolone (Stoletov et al., 2013). In both cases, Cx26 was suggested to
facilitate tumor cell extravasation mediated by heterocellular GJIC with endothelial cells.
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Because of the scarcity of in vivo data on the role of connexins in melanoma and the
complete lack of Cx43-based studies, we utilized the chick chorioallantoic membrane
(CAM) assay to investigate primary tumor growth of connexin-expressing and connexindeficient melanoma cells. This inexpensive and efficient tumor formation assay has been
used by many as a model to study primary melanoma tumor growth and metastasis
(Arpaia et al., 2012; Chambers et al., 1982; Penuela et al., 2012; Stoletov et al., 2013;
Zijlstra et al., 2002). The immunosuppressed chicken embryo acts as a host for foreign
tumor cell engraftment, and its extensive vasculature network provides tumor cells with
in vivo growth factors as well as offering a pathway for metastasis to developing organs
(Karnofsky et al., 1952; Knighton et al., 1977; Leighton, 1964; Scher et al., 1976).

1.13 Hypothesis
We hypothesized that ectopic expression of Cx26 and Cx43 in connexin-deficient
melanoma cells would increase gap junctional intercellular communication (GJIC),
thereby decreasing their tumorigenic properties. To address this hypothesis, we used
replication- defective retroviruses to stably express GFP-tagged Cx26 and Cx43 in an
aggressive, metastatic BL6 mouse melanoma cell line that exhibited compromised GJIC.
Using these connexin-expressing melanoma cell lines, we assessed GJIC using a
microinjection dye transfer assay.

Furthermore, we assessed for several in vitro

tumorigenic behaviors including cell proliferation, migration and anchorage-independent
growth. Using connexin-rich rat epidermal keratinocytes, we developed a co-culture
model to assess for heterocellular GJIC between melanoma cells and keratinocytes and
evaluated melanoma cell growth within this in situ-like microenvironment. Finally, we
measured tumorigenesis in vivo using the chick CAM assay.

1.14 Objectives
1.) Examine the effect of ectopic Cx26 and Cx43 expression in melanoma cells on
GJIC in vitro.
2.) Assess the tumorigenic behavior of Cx26- and Cx43-expressing melanoma cells
in vitro and within the in situ-like microenvironment of keratinocytes.
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3.) Assess the tumorigenicity of Cx26- and Cx43-expressing melanoma cells within
the in vivo chicken embryo model.
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Chapter 2

2

Connexin43 Reduces Melanoma Growth in a
Keratinocyte Microenvironment and During
Tumorigenesis in vivo

Connexins have been identified as tumor suppressors and enhancers, a distinction that
appears to be dependent on the type and stage of disease. However, the role of connexins
in melanoma tumorigenesis and their status during cancer onset and progression remains
controversial and unclear. Here, we show that the aggressive B16-BL6 mouse melanoma
cell line expresses low basal levels of Cx26 and Cx43 rendering them gap junctional
intercellular communication (GJIC) deficient as elucidated by immunofluorescence,
Western blotting and dye transfer studies.

Following ectopic expression of green

fluorescent protein (GFP)-tagged Cx26 and Cx43 in these connexin-deficient melanoma
cells, punctate gap junction-like plaques were evident at sites of cell-cell apposition and
the incidence of dye transfer was significantly increased similar to connexin-rich
keratinocytes. We found that the expression of Cx43, but not Cx26, significantly reduced
cellular proliferation and anchorage-independent growth from control melanoma cells,
whereas migration was unaffected.

Additionally, melanoma cells expressing Cx43

displayed significantly reduced growth within the in situ-like microenvironment of
keratinocytes, despite a complete lack of heterocellular GJIC between the two cell types.
Furthermore, when grown in vivo in the chicken embryo, primary tumors that formed in
the chorioallantoic membrane derived from Cx43-expressing melanoma cells were
significantly smaller than controls, whereas Cx26-expressing melanoma cells produced
tumors similar to controls. Collectively, these results suggest that Cx43, and not Cx26,
can act as a tumor suppressor during melanoma tumorigenesis.

A version of this chapter was submitted to the Journal of Biological Chemistry
Ableser MJ, Penuela S, Lee J, Shao Q, Laird DW. Cx43 reduces melanoma growth in a
keratinocyte microenvironment and during tumorigenesis in vivo. (submitted).

32

2.1 Introduction
Connexins (Cx) are a family of integral membrane proteins that can oligomerize into
hexamers, known as connexons, which dock with connexons from apposing cells forming
gap junction channels (Sohl and Willecke, 2003). The gap junction-mediated exchange
of small molecules (< 1 kDa) between cells is known as gap junctional intercellular
communication (GJIC), and this process is critical for the maintenance of cellular
homeostasis and regulation of controlled cellular events including proliferation,
differentiation and apoptosis (Sohl and Willecke, 2003).

Although it is commonly

accepted that the primary function of connexins is to assemble into gap junctions to allow
for GJIC, connexons also possess the ability to act as single-membrane hemichannels
allowing for the exchange of signaling molecules with the extracellular environment
(Wang et al., 2013). The human genome encodes 21 distinct connexins, which are
expressed in some combination in virtually all cell types of the body (Sohl and Willecke,
2003). Interestingly, as many as 10 connexins, including Cx26 and Cx43, are expressed
in human epidermis with a similar subset expressed in rodent epidermis (Richard, 2000).
Primarily, these connexins are expressed by keratinocytes and are differentially regulated
within the different epidermal strata (Richard, 2000). Additionally, melanocytes, which
reside in the basal layer of the epidermis, have been reported to only express Cx26 and
Cx43 (Hsu et al., 2000a; Masuda et al., 2001). Typically, one melanocyte establishes
contacts with approximately 30 keratinocytes within the basal and suprabasal layers
forming the ‘epidermal-melanin unit’ (Haass and Herlyn, 2005) and the connexin
compatibilities of the two cell types render them capable of heterocellular GJIC (Hsu et
al., 2000a).

It is commonly believed that melanocyte growth is controlled by

keratinocytes through GJIC (Haass and Herlyn, 2005) as well as the exchange of other
regulatory signals (Seiberg et al., 2000; Shih et al., 1994).
Gap junctions were first implicated as being important in tumorigenesis nearly 50 years
ago (Loewenstein and Kanno, 1966). Since then, many investigators have reported that
connexins are down-regulated or even absent in cancer cell lines resulting in
compromised GJIC (Cronier et al., 2009; Krutovskikh et al., 1994; Loewenstein and
Kanno, 1966; Mesnil et al., 2005; Yamaoka et al., 1995), and also observed reductions in
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tumorigenic behaviors when connexins were ectopically re-introduced into tumor cells
(Eghbali et al., 1991; Hirschi et al., 1996; Loewenstein and Rose, 1992; McLachlan et al.,
2006; Zhu et al., 1991). These findings, combined with the observations that Cx32knockout mice are more prone to developing chemical- and radiation-induced tumors
(King and Lampe, 2004a; Temme et al., 1997), support the notion that connexins have
tumor suppressor properties. However, more recently, connexins have been shown to
facilitate tumor progression and metastasis in late-stage disease leading to their
reclassification as conditional tumor suppressors (Naus and Laird, 2010). Given this
paradox, it is not surprising to find that the role of connexins during the onset and
progression of melanoma tumorigenesis is controversial and remains poorly understood.
Although the majority of research suggests that melanomas exhibit poor GJIC due to
connexin deficiencies (Bagnato et al., 2004; Hsu et al., 2000a; Ito et al., 2000; Su et al.,
2000), some studies suggest that connexins may be facilitators of late stage disease (Ito et
al., 2000; Saito-Katsuragi et al., 2007; Stoletov et al., 2013), alluding to a potential
biphasic role of connexins during melanoma tumorigenesis.
When studying tumorigenesis, it is important to consider the in situ tumor cell
microenvironment in order to account for contact-dependent and diffusible factors that
may influence tumor growth and progression. In particular, when studying the role of
connexins in tumorigenesis, the in situ microenvironment takes on further importance as
direct cell-to-cell contact is needed to facilitate GJIC. In the case of melanoma, the loss
of the ability to form heterocellular contacts and exhibit GJIC with keratinocytes may be
a contributor to melanoma growth within the epidermis (Hsu et al., 2000a; Hsu et al.,
2000b) whereas GJIC between melanoma cells and fibroblasts or endothelial cells may
enhance tumor progression and metastasis (Ito et al., 2000; Saito-Katsuragi et al., 2007;
Stoletov et al., 2013).

Thus, it is imperative to study connexins during melanoma

tumorigenesis in a multidimensional context that encompasses in situ and in vivo
environments to better understand how tumor cells behave during cancer progression
while also in the setting of normal cell types.
Using this approach, we sought to further assess the role of connexins and GJIC during
melanoma

tumorigenesis

in

a

unifying

model

mindful

of

the

melanoma
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microenvironment. We found that the metastatic B16-BL6 mouse melanoma cell line
(BL6) expressed only low basal levels of Cx26 and Cx43 rendering them GJIC-deficient.
Following ectopic expression of both connexins, we established GJIC amongst melanoma
cells, but this failed to restore GJIC with keratinocytes. The expression of Cx43 in
melanoma cells significantly reduced proliferation and anchorage-independent growth in
vitro, reduced growth within the in situ-like microenvironment of keratinocytes and
reduced primary tumor size within the in vivo microenvironment of the chicken embryo.
Conversely, the expression of Cx26 did not affect the aggressive behavior and
tumorigenic properties of melanoma cells. Taken together, these studies strongly suggest
that Cx43, but not Cx26, is capable of suppressing melanoma tumorigenesis.

2.2 Materials and Methods
2.2.1

Cell culture

The murine melanoma cell line B16-BL6 (kindly provided by Dr. Moulay Alaoui-Jamali,
McGill University) was cultured in Minimal Eagle’s Medium (MEM) containing 2 mM
L-glutamate, 10% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, 0.1 mM MEM
non-essential amino acids, MEM vitamin solution and 1 mM MEM sodium pyruvate
(Invitrogen, Carlsbad, CA). Rat epidermal keratinocytes (REK, kindly provided by Dr.
Vincent Hascall, Cleveland Clinic Foundation) were cultured in Dulbecco’s Modified
Eagle’s Medium with 4.5 g/L glucose 1X (DMEM) supplemented with 2mM Lglutamate, 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin (Invitrogen).
All cells were incubated at 37°C and 5.0% CO2.

2.2.2

Generation of connexin-expressing melanoma cell lines

BL6 cells were stably infected with an empty AP2 replication-defective vector or vectors
encoding Cx43 or Cx26 fused to monomeric GFP (Cx43-GFP or Cx26-GFP,
respectively) as previously described (Thomas et al., 2005). Due to the heterogeneous
nature of the retroviral infection, cells were grown into isolated colonies in order to select
for cells which displayed strong Cx26-GFP and Cx43-GFP expression with characteristic
cell surface localization.

Briefly, newly engineered Cx26-GFP and Cx43-GFP

expressing cells were plated at very low density in 10 cm dishes and allowed to grow into
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isolated colonies for two weeks. Using an inverted epifluorescence microscope (Leica
Microsystems, Wetzlar, Germany), isolated colonies enriched in GFP expression were
identified and subsequently picked and allowed to expand in 12-well plates. Of the
isolated colonies selected, the Cx26- and Cx43-expressing colonies that were most
enriched in GFP expression were determined and used for the remainder of the
experiments.

2.2.3

Immunocytochemistry, confocal microscopy and western
blotting

Control and connexin over-expressing melanoma cells were cultured on coverslips,
grown to confluence and fixed in 10% formalin.

Fixed cells were blocked and

permeabilized with 3% bovine serum albumin (BSA)/0.1% Triton X-100 in phosphate
buffered saline (PBS) for 1 h and immunolabeled with rabbit anti-Cx26 (1:200 dilution,
Invitrogen 51-2800), rabbit anti-Cx43 (1:500 dilution, Sigma) and/or mouse anti-Ncadherin (1:200 dilution, BD Transduction Laboratories, Mississauga, ON) antibodies for
1 h at room temperature, followed by incubation with Alexa Fluor® 488-conjugated antirabbit (1:500 dilution, Molecular Probes, Eugene, ORz) or Alexa Fluor® 555-conjugated
anti-mouse (1:1000 dilution, Molecular Probes) secondary antibodies.

Nuclei were

stained with Hoechst 33342 dye prior to mounting on glass slides with Airvol.
Immunolabeled coverslips were imaged using a Zeiss LSM 510 inverted confocal
microscope (Carl Zeiss AG, Oberkochen, Germany) using a 63X objective lens to
determine connexin localization.
In the case of western blotting, protein lysates were collected from confluent monolayers
(or over-confluent cultures of REKs to stimulate keratinocyte differentiation leading to
the expression of Cx26) in a lysis buffer [1% Triton X-100, 150mM sodium chloride
(NaCl), 10mM tris(hydroxymethyl)aminomethane (Tris)/hydrogen chloride (HCl) (pH
7.4), 1mM ethylenediaminetetraacetic acid (EDTA), 1mM ethylene glycol tetraacetic
acid (EGTA) and 0.5% Nonidet P40, supplemented with protease inhibitor mixture
(Roche Applied Sciences, Penzberg, Germany) and phosphatase inhibitors (1 mM sodium
fluoride and 1 mM sodium orthovanadate)]. Protein concentrations were determined
using a bicinchoninic acid (BCA) protein determination kit (Pierce, Rockford, IL). Total
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protein lysates (35 or 50 µg) were resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS/PAGE) and transferred onto nitrocellulose membranes using the
iBlot Dry Blotting System (Invitrogen). Membranes were blocked using 5% Blotto,
Nonfat Dry Milk (Santa Cruz Biotechnology, Dallas, TX) for 1 h before being
immunolabeled with rabbit anti-Cx26 (1:1000 dilution, Invitrogen 71-0500), rabbit antiCx43 (1:5000 dilution, Sigma-Aldrich, St. Louis, MO), mouse anti-GFP (1:7500 dilution,
Millipore) or mouse anti-β-tubulin (1:7500 dilution, Sigma) antibodies at 4°C. Primary
antibodies were detected using the fluorescently conjugated anti-rabbit Alexa Fluor® 680
(1:10,000 dilution, LI-COR Biosciences, Lincoln, NB) or anti-mouse IRdye 800
(1:10,000 dilution, LI-COR Biosciences) antibodies and scanned using the Odyssey
Infrared Imaging System (LI-COR Biosciences).

2.2.4

Microinjection and dye transfer

Cells grown to confluence were microinjected with 10mM Alexa Fluor® 350 hydrazide
(Molecular Probes), which is known to permeate through gap junctions (Harris, 2007),
using an Eppendorf Femojet automated pressure microinjector. Images were collected
using a Leica DM IRE2 inverted epifluorescence microscope using a 20X objective lens
equipped with Openlab 5.5.3 imaging software. The percentage of cells that passed dye
to at least one neighboring cell was recorded. For each biological replicate, 15 injections
were performed on each cell line and statistical analysis was performed on the average of
three biological replicates.

2.2.5

Growth curves and proliferation

Cells were plated into individual wells of a 6-well plate at a density of 1 x 104 cells/well.
On days 2, 4, 5 and 6, cells were lifted from the plate with 500 µL of 0.25% trypsinEDTA (Invitrogen) and counted using a Countess Automated Cell Counter (Invitrogen)
or supplemented with fresh media. Statistical analysis was performed on the average of
two technical replicates of four biological replicates. In parallel, cells were plated on
coverslips at a density of 1 x 104 cells/well. On day 4, cells were incubated with fresh
media containing 1 µg/mL 5-ethynyl-2´-deoxyuridine (EdU) for 3 h and subsequently
fixed in 3.7% formalin for 15 minutes at room temperature. Cells were labeled using the
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Click-It® EdU Alexa Fluor® 488 Cell Proliferation Kit (Molecular Probes) according to
the manufactures instructions. The fluorescence of GFP within the engineered cells was
quenched due to the intensity of the fluorescence from the conjugated Alexa Fluor® 488
azide. As such, in order to visualize the presence of GFP, cells were countered-stained
with a mouse anti-GFP (1:500 dilution, Millipore) antibody followed by an Alexa Fluor®
555-conjugated anti-mouse (1:1000 dilution, Molecular Probes) antibody. Images were
collected using a Leica DM IRE2 inverted epifluorescence microscope equipped with
Openlab 5.5.3 imaging software. For each biological replicate, 10 blinded, randomized
images were taken using the 63X objective lens and the percentage of EdU-positive cells
compared to total nuclei were counted using ImageJ 1.46r (NIH, Bethesda, MD).
Statistical analysis was performed on the average of four biological replicates.

2.2.6

Anchorage-independent growth

BL6 cells were plated at a density of 1 x 104 cells/well in 0.3% soft agar suspension atop
a polymerized 0.4% soft agar layer. For each biological replicate, BL6 cells were plated
in six wells for each treatment.

Cultures were grown for 10 days under normal

conditions. Images were collected using a Leica DM IRE2 inverted epifluorescence
microscope and Openlab 5.5.3 imaging software. For each well, 10 randomized images
were taken with a 5X objective lens. Colonies that were greater than 50 µm in diameter
were counted and the average number of colonies/mm2 was determined. Statistical
analysis was performed on the average of four biological replicates.

2.2.7

Migration scratch assay

Control and engineered BL6 cells were plated on etched grid-plates and grown to
confluence prior to treating with 25 µg/mL Mitomycin C (Sigma), a mitotic inhibitor, for
30 min in normal media. Cells were scraped along a straight line down the midline of the
grid-plate with a rubber cell scraper, clearing half the plate of cells. Cells were then
supplemented with serum-free MEM. Five intersecting grid-points were marked along
the scrape edge as reference points. Images were collected using a Leica DM IRE2
inverted epifluorescence microscope equipped with Openlab 5.5.3 imaging software.
Images were taken at each reference point (0, 24 and 48 hours) using a 5X objective lens.
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For each reference point, the distance from the scrape edge (0 h) to the leading migratory
edge (24 and 48 hrs) was measured using ImageJ 1.46r (NIH). Statistical analysis was
performed on the average of four biological replicates.

2.2.8

Co-culture melanoma growth

REKs were plated at a density of 5 x 104 cells/well and co-cultured with BL6 cells at a
density of 1 x 104 cell/well. Mixed cell cultures were supplemented with DMEM and
MEM at a 4:1 ratio, respectively, and were grown for 6 days to confluence. Clusters
were identified under phase contrast due to their morphological differences, and their
melanoma phenotype was confirmed by the presence of GFP-tagged connexins in
engineered cells. For each biological replicate, 10 blinded, randomized images were
taken using a 5X lens. Under phase contrast, melanoma clusters were outlined using
ImageJ 1.46r (NIH) and the total area of all melanoma clusters for a given field was
determined. Statistical analysis was performed on the average area occupied by BL6
cells of four biological replicates.

2.2.9

Co-culture microinjections and dye transfer

REKs were co-cultured with BL6 cells at a 10:1 ratio, respectively. Mixed cell cultures
were supplemented with DMEM and MEM at a 4:1 ratio, respectively, and allowed to
grow to confluence. Melanoma clusters were identified under phase contrast due to their
morphological differences, which was confirmed by the presence of GFP-tagged
connexins in engineered cells.

BL6 cells or REKs at the melanoma-keratinocyte

boundary were microinjected with 10nM Alexa Fluor® 350 hydrazide (Molecular Probes)
using an Eppendorf Femojet automated pressure microinjector. Images were collected
using a Leica DM IRE2 inverted epifluorescence microscope using a 20X objective lens
equipped with Openlab 5.5.3 imaging software. The percentage of injected BL6 cells
that passed dye to at least one neighboring BL6 or REK was recorded. Similarly, the
percentage of injected REKs that passed dye to at least one neighboring REK or BL6 was
recorded. For each biological replicate, at least 6 REKs and 6 BL6 cells were injected.
Statistical analysis was not performed due to a complete lack of heterocellular dye
transfer between different cell types over three biological replicates.
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2.2.10

In vivo chick chorioallantoic membrane (CAM) assay

Primary tumor properties of BL6 cells were assessed in the chicken embryo as previously
described (Penuela et al., 2012). Briefly, fertilized chicken eggs (McKinley Hatchery, St.
Mary’s, ON) were incubated in an automated rotary incubator (GQF Manufacturing
Company, Savannah, GA) under 40% humidity at 37°C for 3 days, rotating once every
hour. Eggs were removed from their shell and placed in covered dishes. Chicken
embryos were incubated for an additional 7 days in stationary incubators (GQF
Manufacturing Company) under 60% humidity at 37°C. On day 11 of development, 3.0
x 105 control or connexin-expressing BL6 cells in 20 µL of serum-free MEM were
topically applied to a site of major branching vessels on the CAM distal to the embryo
and covered with a coverslip.

The embryos were returned to a humidified 37°C

stationary incubator for 7 days to allow tumor growth. Primary melanoma tumors that
formed at the site of topical application were excised and weighed. Statistical analysis
was performed on the primary tumor weights of 18 control, 15 Cx43-GFP, and 12 Cx26GFP expressing melanoma tumors.

2.2.11

Statistics

Statistical analysis was performed on all data using a one-way ANOVA followed by a
Tukey’s post-hoc test in which p < 0.05 was considered significant. Values are presented
as means ± S.E.M. All statistics were performed using GraphPad Prism Version 4.03 for
Windows.

2.3 Results
2.3.1

Expression of Cx26 and Cx43 increases gap junction plaque
formation and GJIC in mouse melanoma cells

The mouse melanoma cell line B16-BL6 expressed low levels of both Cx26 and Cx43 as
indicated by immunofluorescence (Fig. 2.1A) and western blot analysis (Fig. 2.1B,C).
Cx26 was observed only in over-confluent REKs while Cx43 was readily detectable in
these cells (Fig. 2.1A, inserts). Following ectopic expression of Cx26-GFP and Cx43GFP, BL6 cells exhibited punctate gap junction-like structures that localized to the cell
surface as indicated by their co-localization with the cell adhesion molecule N-cadherin
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Figure 2.1 BL6 mouse melanoma cells express low levels of Cx26 and Cx43.
Immunofluorescence revealed that wild-type (WT) BL6 cells endogenously express low
levels of Cx26 and Cx43 (A) compared to REKs which display typical gap junctional
plaques at sites of cell-cell apposition (A, inserts). Western blots confirmed low levels of
Cx26 (B) and Cx43 (C) in melanoma cells compared to lysates collected from overconfluent and confluent REK cultures, respectively. Following ectopic expression of
Cx26-GFP or Cx43-GFP, punctate gap junction-like plaques were evident at the cell
surface as denoted by the cell adhesion molecule N-cadherin (red) (A, arrows; blue,
nuclei) and the expression of GFP-tagged connexins were readily detected by western
blots immunolabeled for Cx26 (B) or Cx43 (C). Additionally, both fusion proteins were
expressed at similar levels as detected by western blots immunolabeled for GFP (D). βtubulin was used as loading control. The vector control represents cells transfected with
a construct that did not encode connexins. Lanes separated by vertical lines were run on
the same blot but spliced together.

Lanes loaded with REK lysates were run as

independent experiments. Scale bars = 20 µm.
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(Fig. 2.1A, arrows). Western blots revealed low levels of Cx26 and Cx43 in BL6 cells
compared to REKs, while both Cx26-GFP and Cx43-GFP were readily detected
following their ectopic expression (Fig. 2.1B,C). Additionally, both fusion proteins
displayed similar expression levels when probed for GFP (Fig. 2.1D).
To assess the GJIC capacity of control and engineered cells, all cell lines were
microinjected with the small molecular dye Alexa350 and the incidence of dye transfer to
neighboring cells was measured. Wild-type and vector control BL6 cells were found to
be GJIC-deficient, only passing dye from ~25% of the microinjected cells (Fig. 2.2A,
arrows). Conversely, Cx26-GFP and Cx43-GFP expressing melanoma cells displayed
significantly increased dye transfer resulting in 80% and 100% of the microinjected cells
passing dye to neighboring cells, respectively (p < 0.05). The Cx26 and Cx43 engineered
cells acquired a GJIC status that was statistically similar to Cx43-rich and well coupled
REKs (Fig. 2.2B).

Thus, our findings show that both Cx26 and Cx43 are able to

establish functional GJIC in BL6 cells.

2.3.2

Cx43 expression in melanoma cells significantly reduces cell
proliferation

When subjected to a 6-day growth curve analysis, Cx43-expressing BL6 cells displayed
significantly reduced total cell number compared to controls as early as day 4 (p < 0.05),
which was further amplified on days 5 and 6 (2.5-fold; p < 0.001). Conversely, Cx26 did
not impart as profound an effect on total cell number but there was a slight reduction of
~20% in cell number on day 6 (p < 0.05) (Fig. 2.3A).
To determine if the effect of Cx43 on total cell numbers was due to changes in cell
proliferation, we used an EdU labeling assay at day 4 to determine the number of cells
actively cycling through the synthesis phase (S-phase) of the cell cycle. We found that
the expression of Cx43 in BL6 cells significantly reduced the percentage of EdU+ cells
by ~25% from controls (p < 0.01) (Fig. 2.3B,C). Consistent with our growth curve
analysis, the expression of Cx26 did not significantly reduce the percentage of EdU+
cells (Fig. 2.3C). Collectively, Cx43 was found to reduce total cell numbers by reducing
the rate at which cells pass through S-phase of the cell cycle.
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Figure 2.2 Ectopic connexin expression significantly increases GJIC.
Alexa350 dye transfer studies revealed that wild-type and control melanoma cells were
poorly coupled, as dye rarely spread from the microinjected cell (arrows) to neighboring
cells (A). Following ectopic expression of Cx26-GFP or Cx43-GFP, the incidence of dye
transfer was significantly increased to 80% and 100%, respectively, statistically similar to
Cx43-rich REK controls (N = 3, p < 0.05) (B). Phase contrast images depict cellular
morphology prior to microinjection while the GFP fluorescence denotes the expression of
ectopic connexins. Letters depict statistical significance among groups. Scale bars = 40
µm.
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Figure 2.3 Expression of Cx43 significantly reduces total cell number and cell
proliferation.
Six day growth curves revealed that Cx43-expressing melanoma cells displayed
significantly reduced total cell number as early as day 4 (N = 4, *, p < 0.05), which was
further reduced on days 5 and 6 (N = 4, ***, p < 0.001). Cx26-expressing melanoma
cells displayed a slight reduction in total cell number only on day 6 (N = 4, *, p < 0.05)
(A). Proliferation at day 4 was assessed using an EdU assay, which labels nuclei passing
through S-phase of the cell cycle, where the proportion of EdU labeled nuclei (green) to
total nuclei labeled with Hoechst (blue) was determined (B). Cells were counter-stained
with an anti-GFP antibody (red) as the normal fluorescence of GFP-tagged Cx43 was
quenched by the EdU signal. Expression of Cx43 significantly reduced the percentage of
EdU-positive cells by ~25% in comparison to the controls (N = 4, **, p < 0.01) (C). Scale
bars = 20 µm.
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2.3.3

Cx43-expressing melanoma cells display a reduced
malignant phenotype

When grown in soft agar suspension to assess for anchorage-independent growth, the
amount of colonies formed from Cx43-expressing melanoma cells was significantly
reduced by ~4.5-fold from controls (p < 0.001). Conversely, the expression of Cx26 in
BL6 cells did not significantly reduce anchorage-independent growth (Fig. 2.4A and B).
Using a scratch assay, the migratory distance from the wound edge at 0 h (Fig. 2.4C, left
panel, red line) to the leading edge at 48 h (Fig. 2.4C, right panel, red line) was not
statistically different between control and Cx-expressing melanoma cells (Fig. 2.4D).

2.3.4

Cx43 expression in melanoma cells reduces growth in an in
situ-like microenvironment independent of heterocellular
GJIC with keratinocytes

BL6 cells were co-cultured at a low density with REKs and allowed to grow to
confluence over 6 days.

Identifiable clusters were observed under phase contrast (Fig.

2.5A, left column, dashed lines) and their melanoma phenotype was confirmed due to the
expression of GFP-tagged connexins within the outlined areas in engineered cells. Wildtype and control melanoma cells were found to occupy approximately 14% of the 2dimensional field of view. Melanoma cells expressing Cx26 did not grow as robustly as
control melanoma cells in the context of the keratinocytes and were found to occupy
slightly reduced area, although this was not statistically significant.

However, the

expression of Cx43 significantly reduced the total area occupied by melanoma cell
clusters by ~4.5-fold compared to controls (p < 0.05) (Fig. 2.5A and B).
Using this co-culture model, we assessed for heterocellular GJIC between melanoma
cells and keratinocytes by microinjecting both cell types at the melanoma-keratinocyte
interface. Again, when BL6 cells were co-cultured with Cx-rich REKs, identifiable
melanoma cell clusters were observed under phase contrast (Fig. 2.6, left column, dashed
lines). As expected, connexin-deficient melanoma cells were poorly coupled to each
other and did not transfer Alexa350 dye to the Cx43-rich keratinocytes. While connexinexpressing melanoma cells displayed high incidences of dye transfer with neighboring
melanoma cells, in all cases, they failed to pass dye to adjacent keratinocytes. Similarly,
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Figure 2.4 Cx43 expression significantly reduces anchorage-independent growth
while cell migration remains unaffected.
When grown in soft agar suspension for 10 days, colonies were evident under phase
contrast and those formed from Cx-expressing melanoma cells were GFP-positive (A).
The number of colonies formed was significantly reduced in melanoma cells expressing
Cx43 by ~4.5-fold in comparison to controls (N = 4, ***, p < 0.001), whereas Cx26
expression did not significantly alter the number of formed colonies (N = 4, p = ns) (B).
Using a migration scratch assay, the migratory ability of Cx-deficient and Cx-expressing
melanoma cells was assessed. Cells were grown to confluence, pulsed with 25 µg/mL of
Mitomycin C for 30 minutes, scratched (C, red line at 0 hrs) and supplemented with
serum-free media. The distance migrated from the initial scratch edge to the leading edge
after 24 and 48 hours (C, red line at 48 hrs) was not statistically different between Cxdeficient and Cx-expressing melanoma cells (N = 4, p = ns) (D). Scale bars = 200 µm.
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Figure 2.5 Expression of Cx43 significantly reduces melanoma cell growth within a
keratinocyte-based microenvironment.
Melanoma cells were co-cultured with keratinocytes at a 1:5 ratio and allowed to grow
for 6 days. Under phase-contrast imaging, melanoma cell clusters were identifiable
(dashed lines) and their melanoma phenotype was confirmed in engineered cell lines due
to the expression of GFP (A). The area of all melanoma cell clusters for a given field
was measured and Cx43-expressing melanoma cells were found to occupy ~4.5-fold less
area than controls (N = 4, *, p < 0.05) (B). Scale bars = 200 µm.
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Figure 2.6 Ectopic connexin expression in melanoma cells does not affect
heterocellular GJIC with keratinocytes.
Melanoma cells were co-cultured with keratinocytes at a 1:10 ratio, respectively. Under
phase contrast, melanoma cell clusters were identifiable (dashed lines) and their
melanoma phenotype was confirmed, where possible, by the expression of GFP. In all
cases, injected melanoma cells (arrows) failed to pass Alexa350 to adjacent
keratinocytes, and only Cx-expressing melanoma cells exhibited sufficient dye transfer
amongst each other (N = 3).

Similarly, keratinocytes injected with Alexa350

(arrowheads) were highly coupled with neighboring keratinocytes, but in all cases, failed
to pass dye to adjacent melanoma cell (N = 3). Scale bars = 50 µm.
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when keratinocytes were injected at the melanoma-keratinocyte border, REKs were
highly coupled with neighboring REKs, but never transferred dye to adjacent melanoma
cells, regardless of connexin status (Fig. 2.6).

2.3.5

Cx43-expressing melanoma cells display reduced primary
tumor size in vivo

Using the in vivo chicken embryo model, control or connexin-expressing melanoma cells
were topically applied to the CAM of 10-day old embryos and allowed to grow for one
week. In all cases, primary tumors formed at the sight of topical application (Fig. 2.7A,
arrows). Primary tumors were excised and excess CAM was removed from the tumor
mass. Embryos inoculated with control melanoma cells produced large, highly
vascularized tumors averaging 0.09 ± SEM g in weight. The expression of Cx26 within
these tumors did not significantly reduce primary tumor weights in the chick-CAM assay.
Conversely, Cx43-expressing melanomas exhibited significantly reduced primary tumor
weight, producing tumors on average of 0.02 ± SEM g, which represents a reduction in
tumor mass of ~4.5-fold compared to the vector control (p < 0.001) (Fig. 2.7A and B).
These tumors appeared more diffuse, less vascularized, and occasionally less pigmented.
Together, these studies suggest that Cx43 is a potent tumor suppressor in melanoma cells
in the in situ-like microenvironment of keratinocytes as well as in vivo.

2.4 Discussion
The role of connexins in melanoma tumorigenesis remains poorly understood as some
studies support the notion that connexins behave as tumor suppressors while other reports
suggest that connexins in melanomas facilitate the spread of the disease during metastasis
(Bagnato et al., 2004; Hsu et al., 2000a; Ito et al., 2000; Saito-Katsuragi et al., 2007;
Stoletov et al., 2013; Su et al., 2000). While the connexin family is large, most evidence
suggests that the two prominent connexins in melanocytes are Cx26 and Cx43, which
enables GJIC with keratinocytes (Hsu et al., 2000a; Masuda et al., 2001). This direct
cell-to-cell communication is often lost during melanoma transformation, which appears
to be due to connexin down-regulation (Hsu et al., 2000a; Ito et al., 2000). Most studies
pertaining to connexins in melanomas tend to focus on specific stages of tumorigenesis,
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Figure 2.7 Cx43 expression significantly reduces primary tumor growth in vivo.
Control or Cx-expressing melanoma cells (3 x 105) were topically applied to the CAM of
10-day old chicken embryos. Primary melanoma tumors visible on the CAM 7 days
post-inoculation (arrows) were excised, photographed and weighed (A).

Control

melanoma cells produced large, highly vascularized tumors of 0.09 ± SEM g in weight
(N = 18). Cx26-expressing melanomas exhibited a slight reduction in primary tumor
weight (0.075 ± SEM g) but this was not statistically significant (N = 12, p > 0.05).
Conversely, melanoma cells expressing Cx43 produced significantly smaller tumors of
0.02 ± SEM g in weight (~4.5-fold reduction from controls) (N = 15, ***, p < 0.001) (B).
Scale bars = 1 cm.
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however, no previous studies have investigated the role of connexins in a unifying model
system where connexin-expressing melanoma cells are evaluated in vitro, within the
context of keratinocytes and in vivo. Here, we show that Cx43, but not Cx26, is an
effective tumor suppressor in melanoma cells that reside in the context of keratinocytes
and in vivo.
In the present study we chose to ectopically express GFP-tagged Cx26 and Cx43 in an
aggressive, gap junction-deficient BL6 mouse melanoma cell line. Previously, we and
others have shown that the GFP tag exhibited negligible changes to the function and
localization of both these connexins (Laird et al., 2001; Thomas et al., 2005).

As

expected, both connexins readily assembled into gap junctions and established extensive
functional GJIC as assessed by dye transfer assays. In our study, we assessed for the
incidence of dye transfer, and not degree of dye spread, due to the intrinsic differences
between the two connexins in question. Firstly, Cx26 channels are expected to be more
restrictive in the passage of transjunctional molecules in comparison to Cx43 channels
due to their smaller pore size (Weber et al., 2004). Additionally, it is possible that this
feature may be more exacerbated by the attachment of GFP to the much smaller carboxyterminal tail of Cx26 (Naus and Laird, 2010). Regardless, both connexins were shown to
significantly increase dye transfer, similar to connexin-rich keratinocytes.
Since connexins have been defined as conditional tumor suppressors (Naus and Laird,
2010) it is possible that their effects on cell characteristics associated with tumorigenesis
may vary in early and late stage disease as has been suggested to occur in melanomas (Ito
et al., 2000).

Many connexin family members have been reported to inhibit cell

proliferation in several cancer cell types (Eghbali et al., 1991; Sato et al., 2007). To that
end, ectopic expression of Cx43 has been shown to reduce cell proliferation in many
distinct cancers (Huang et al., 1998; Ionta et al., 2009; Zhu et al., 1991). Here, we show
that Cx43 expression in Cx-deficient melanomas reduces total cell number via delayed
passage through the S-phase of the cell cycle. Likewise, the expression of Cx26 in
cancer cells has also been reported to reduce cell proliferation (Kalra et al., 2006), as has
the related and often co-expressed Cx30 isoform (Princen et al., 2001). However, here
we found that Cx26 exhibited no significant effect on cell proliferation in melanoma
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cells, suggesting tumor cell specific differences. Mechanistically, it has been suggested
that Cx43 reduces proliferation in glioblastomas by inhibiting cell cycle progression
through GJIC-independent mechanisms (Huang et al., 1998).

These findings are

consistent with later studies where Cx43 was suggested to control cell cycle progression
at the first growth phase through increased expression of p27, a cyclin-dependent kinase
inhibitor, as a result of the inhibition of the S-phase kinase associated protein, Skp2
(Zhang et al., 2003).

Additionally, Cx43 has also been reported to decrease the

expression of several cyclins and cyclin-dependent kinases in transformed kidney
epithelium (Chen et al., 1995), although the requirement for channel function was not
assessed.
Cx26 has been shown to reduce anchorage-independent growth in several cancer cell
types (McLachlan et al., 2006; Omori and Yamasaki, 1999) as has Cx43 (Huang et al.,
1998; McLachlan et al., 2006; Su et al., 2000). Importantly, Cx43 has been reported to
reduce anchorage-independent growth in melanoma cells (Su et al., 2000) similar to our
results, while Cx26 was not previously assessed. Interestingly, Omori and Yamasaki
(1999) showed that in Henrietta Lacks cervical cancer (HeLa) cells, carboxy-terminally
truncated Cx43 was capable of establishing GJIC and also reduced anchorageindependent growth. Thus, transjunctional passage of molecules is likely causing the
cellular changes rather than binding of one of the many members of the interactome that
have been reported to bind to the carboxy-terminus of Cx43 (Laird, 2010).
In some tumor cell types connexins have also been reported to affect migration. For
example, Cx26, but not Cx43, has been shown to reduce migration in breast tumor cells
(Kalra et al., 2006). Similarly, Zucker et al. (2013) reported that both wild-type Cx43
and a channel-dead Cx43 mutant did not alter migration in melanoma cells. Although
Cx26 and Cx43 do not consistently play a role in melanoma cell migration, as our in vitro
studies show, one must also consider the many factors of the in vivo microenvironment as
connexins have been shown to be up-regulated and correlated to increased melanoma
metastasis (Ito et al., 2000; Saito-Katsuragi et al., 2007; Stoletov et al., 2013). However,
in addition to migration, this complex process encompasses other cellular events in which
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connexins have been deemed important, including extravasation (Elzarrad et al., 2008;
Pollmann et al., 2005).
In the epidermis, the growth and homeostasis of melanocytes (the precursors to
melanoma) is controlled by epidermal keratinocytes which together with melanocytes,
form the ‘epidermal-melanin unit’ (Haass and Herlyn, 2005; Hsu et al., 2000a; Seiberg et
al., 2000). Heterocellular GJIC is established between keratinocytes and melanocytes for
the putative passage of regulatory signals that coordinates the epidermal-melanin unit
(Hsu et al., 2000a). As expected, connexin-deficient melanoma cell clusters that arise are
not only isolated from each other, but also from keratinocytes as we discovered in mixed
cell cultures of these two cell types. Somewhat to our surprise, connexin-expressing
melanoma cells also remained functionally isolated from keratinocytes despite the ability
of both cell types to express both Cx26 and Cx43. Their lack of ability to re-establish
heterocellular GJIC may be due to the cadherin differences between melanoma cells and
keratinocytes, expressing N-cadherin and E-cadherin, respectively, as previously reported
(Hsu et al., 2000a). In support of this concept, it has been reported that melanoma cells
which retained E-cadherin expression, as well as melanoma cells that were engineered to
express E-cadherin, could establish GJIC with keratinocytes (Hsu et al., 2000a),
producing a less malignant phenotype (Hsu et al., 2000b). In contrast to this, we show
that increasing Cx43-based GJIC between melanoma cells can significantly inhibit
melanoma cell growth when grown in the microenvironment of keratinocytes, despite not
re-establishing heterocellular GJIC with keratinocytes. This inhibition of growth in coculture was significantly higher than the moderate growth reduction observed in Cx43expresing melanoma cells grown in isolation.

We postulate that diffusible factors

produced by keratinocytes or contact-dependent signaling acts to enhance the tumor
suppression, which has been shown to control melanocyte growth and proliferation
(Haass et al., 2004).
Since Cx43 reduced the tumorigenic behavior of melanoma cells in vitro and further in
the context of keratinocytes, we sought to assess the tumorigenicity of connexinexpressing melanomas in vivo. The chick CAM avian embryo model has been widely
used as a model for tumorigenesis in vivo, including the assessment of melanoma primary
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tumor growth and metastasis (Penuela et al., 2012; Stoletov et al., 2013). We found that
control melanoma cells produced relatively large, vascularized tumors, not unlike tumors
produced by Cx26-expressing melanoma cells. Conversely, Cx43-expressing melanoma
cells produced significantly smaller, more diffuse tumors, which at times appeared less
vascularized (data not shown). In our in vitro studies, Cx43-expressing melanoma cells
displayed a 2.5-fold reduction in total cell number. Comparatively, these cells produced
4.5-fold smaller tumors in vivo, suggesting again that the tumor suppressive effects of
Cx43 are microenvironment dependent, similar to our mixed culture studies with
keratinocytes.
express

Cx43

Interestingly, the epithelial cells of the CAM have been reported to
(Girolamo

et

al.,

2006),

providing

a

compatible

connexin

microenvironment, although we have no evidence that heterocellular gap junctions form
in vivo. Furthermore, we have shown that Cx43 can reduce angiogenesis in breast cancer
in a 3-dimensional microenvironment (McLachlan et al., 2006). It is possible that these
and other factors present within the in vivo microenvironment produce additive effects
that reduce primary tumor size above the observed proliferative differences in vitro.
Collectively, these data show that Cx43 is a tumor suppressor in melanoma cells found
within the relevant microenvironment of keratinocytes as well as in vivo. Additionally,
we show that Cx26-based GJIC within melanoma cells does not result in tumor
suppression, but rather, tumor suppression occurs due to the specific expression of Cx43
and the formation of Cx43-based gap junction channels. This concept is not surprising
when we consider the differences in transjunctional molecules that are able to pass
through each respective gap junction channel. Not only are Cx43 channels capable of
passing molecules excluded from Cx26 channels, but they also have different relative
permeabilities to the same molecules (Harris, 2007). These differences in transjunctional
molecules and molecular permeability properties undoubtedly lead to differences in gap
junction-mediated cellular signaling and must be considered when evaluating the
channel-dependent role of connexins during tumorigenesis. Additionally, Cx43 has been
reported to interact with over 30 distinct proteins, compared to approximately 5 for Cx26
(Laird, 2010). In fact, several of these Cx43 binding partners have been implicated as
tumor suppressors including caveolin-1 (Langlois et al., 2010), CCN3 (Fu et al., 2004),
tumor susceptibility gene 101 (TSG101) (Leithe et al., 2009) and Src (Kieken et al.,
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2009). Given this, as well as the many anti-proliferative proteins that have been reported
to be co-regulated with Cx43, the tumor suppressive properties of Cx43 are likely
specific to the cancer type and complex, involving both GJIC-dependent and independent
mechanisms. Furthermore, although we did not re-established GJIC between melanoma
cells and keratinocytes in an attempt to mimic GJIC between melanocytes and
keratinocytes as part of normal skin homeostasis (Haass and Herlyn, 2005), we show that
increasing Cx43 expression and GJIC within melanoma cells has tumor suppressive
properties that are further enhanced in the presence of keratinocytes or other in vivo-like
environments. Thus, Cx43 may prove to be a useful target for future drug therapeutics
where Cx43 expression is selectively enhanced in melanomas.
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Chapter 3

3

General Overview

3.1 Discussion, Future Studies and Conclusion
Connexins have long been implicated as tumor suppressors, but the role of connexins in
melanoma tumorigenesis, and their status during cancer onset and progression remains
controversial and poorly understood. Some investigators suggest that connexins are
downregulated in melanoma and act as tumor suppressors (Bagnato et al., 2004; Haass et
al., 2004; Hsu et al., 2000a; Su et al., 2000), whereas others propose a tumor enhancing
role (Ito et al., 2000; Saito-Katsuragi et al., 2007; Stoletov et al., 2013; Villares et al.,
2009). To add to this uncertainty, the identity of which connexins are involved in
melanoma tumorigenesis remains debated, as some suggest a role for Cx26, whereas
others implicate Cx43. It is possible that these contradictions may actually depend on the
stage of disease progression, potentially mimicking the biphasic, ‘conditional tumor
suppressor’ and tumor promoting roles of connexins as proposed in breast cancer (Naus
and Laird, 2010). However, none of these studies assessed multiple connexins in a
comparative approach and typically only focus on specific stages of melanoma
tumorigenesis. In our study, we assessed the role of two connexins, Cx26 and Cx43, on
melanoma cell behavior in vitro, within the relevant in situ-like microenvironment of
keratinocytes, and in vivo. In all cases, we found that Cx43 acts as a potent tumor
suppressor, reducing proliferation and anchorage-independent growth in vitro, reducing
growth amongst keratinocytes and reducing tumor size within the in vivo chicken
embryo. Conversely, Cx26 did not affect melanoma cell behavior or tumorigenesis.
Connexins and GJIC are vital for the maintenance of tissue homeostasis as they regulate
important cellular processes (Goodenough et al., 1996). Aberrant connexin expression
has been shown to cause abnormal proliferation, as in the case of many skin diseases
linked to connexin mutations (Gerido and White, 2004). Because connexins have been
linked to cellular proliferation, it is not surprising that connexins are frequently dysregulated in proliferating tumor cells.

In fact, connexins have been shown to be
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downregulated in many cancer cell types rendering them GJIC-deficient (Cronier et al.,
2009; Loewenstein and Kanno, 1966; Mesnil et al., 2005), and interestingly, their
proliferation is often suppressed following ectopic reintroduction into tumor cells (Huang
et al., 1998; Ionta et al., 2009; Zhu et al., 1991). In our study, we showed that Cx43
reduced proliferation of melanoma cells by reducing the rate of passage through the
synthesis phase of the cell cycle, whereas Cx26-expressing melanoma cells proliferated
similarly to connexin-deficient melanoma cells. Cx43 has been previously been shown to
reduce proliferation in various cancer cell types by altering several cell cycle-related
proteins, including p27, Skp2, as well as other cyclins and cyclin-dependent kinases.
Some of these proteins appear to be regulated by GJIC-independent mechanisms,
whereas others may require channel function (Chen et al., 1995; Huang et al., 1998;
Zhang et al., 2003). However, it is possible that these mechanisms may be cell type
dependent. In the future, to assess the necessity of channel function, we could use a
channel-dead Cx43 mutant (Cx43 T154A) to observe the effects on proliferation, similar
to that performed by Zucker et al. (2013) using genetically-linked pre-metastatic
(WM793B) and metastatic (1205Lu) human melanoma cells. Alternatively, we could use
a C-terminally truncated Cx43 protein that retains channel function, similar to Omori and
Yamasaki (1999) who showed that channel function, and not the carboxy-terminus, can
reduce anchorage-independent growth in HeLa cells. Collectively, these two types of
Cx43 mutants would allow us to determine if the tumor suppressive properties we
observed in melanoma cells was due to GJIC-dependent or -independent mechanisms,
possibly involving a member of the gap junction proteome.
Melanocytes form the epidermal-melanin unit in situ within the epidermis with
approximately 30 keratinocytes, and it is commonly believed that melanocyte growth and
proliferation is controlled by keratinocytes through GJIC, contact-dependent and
diffusible factors (Haass et al., 2005; Seiberg et al., 2000; Shih et al., 1994; Valyi-Nagy
et al., 1993). Interestingly, we showed that Cx43 expression reduced melanoma cell
growth amongst keratinocytes beyond the expected reductions seen in our proliferation
and growth curve studies. However, despite the fact that both cell types expressed Cx43,
heterocellular GJIC was not established between melanoma cells and keratinocytes,
perhaps due to incompatible cadherins between cell types, as previously hypothesized
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(Hsu et al., 2000a). This would suggest that the additional growth suppression seen in
Cx43-expressing melanoma cells when cultured in a keratinocyte microenvironment was
due to signals received from keratinocytes in a GJIC-independent manner. Such signals
could, in turn, potentially propagate throughout the tumor cells via GJIC. Going forward,
to determine the mechanism by which keratinocytes reduced the growth of Cx43expressing melanoma cells, we could culture these cells with conditioned media from
keratinocytes and re-evaluate melanoma cell proliferation. Such a study would help
elucidate the possible presence of a soluble or contact-dependent factor that may act on
melanoma cells.
The in vivo chick CAM assay has been widely used as a model to study tumorigenesis in
many cancers, including primary melanoma tumor formation and metastasis (Arpaia et
al., 2012; Chambers et al., 1992; Chambers et al., 1982; Penuela et al., 2012; Stoletov et
al., 2013; Zijlstra et al., 2002). This inexpensive and time-efficient model offers an
immunosuppressed host that permits the growth of foreign tumor cells, but more
importantly, provides a highly vascularized system that can provide in vivo factors that
approximately recapitulate in situ tumor growth (Karnofsky et al., 1952; Knighton et al.,
1977; Leighton, 1964; Scher et al., 1976). In our study, we showed that Cx43-expressing
melanoma cells produced ~4.5-fold smaller tumors within the chick-CAM assay
compared to controls, whereas the expression of Cx26 did not significantly alter primary
tumor formation. Similar to our mixed culture studies with keratinocytes, the reduction
in tumor size appeared to be further enhanced in the in vivo setting compared to the
observed reductions in proliferation and cell number in vitro. It is clear that these
differences can be attributed to the microenvironment, which is known to affect tumor
cell growth and proliferation (Allinen et al., 2004). The CAM, formed from the fusion of
the chorionic and allantoic membranes in the developing chicken, encompass portions of
the three embryonic germ layers (Gabrielli et al., 2001). Interestingly, the epithelial cells
within the ectoderm and endoderm of the CAM have been reported to express Cx43
(Girolamo et al., 2006), creating a connexin complement to Cx43 expressed in the
melanomas. However, whether or not these epithelial cells are capable of GJIC with
Cx43-expressing melanoma cells remains to be seen. Previously, it has been shown that
Cx43 expression in breast cancer cells can reduce angiogenesis within a 3-dimensional
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microenvironment (McLachlan et al., 2006), which could result in further reduced tumor
growth within the vascularized CAM. It is possible that these and other mechanisms of
Cx43-based tumor suppression in vivo may require channel function. To test this, we
could employ the use of channel-dead and truncated Cx43 mutants, as outlined earlier. In
addition, the nature of the topical tumor growth in the CAM lends itself to the use of
pharmacological agents that could block gap junction channel function (Storgard et al.,
2005), which could be further used to test the role of gap junction channels in
tumorigenesis. To that end, we could use pharmacological connexin-channel blockers,
such as carbenoxolone, to determine the effect of GJIC on in vivo tumor formation.
One of the major questions left unanswered from our studies is the role of connexins in
melanoma metastasis. Recently, several studies suggest that connexins may actually
facilitate the later stages of tumorigenesis (Elzarrad et al., 2008; Ezumi et al., 2008; Lin
et al., 2002; Pollmann et al., 2005), leading to their reclassification as conditional tumor
suppressors in breast cancer (Naus and Laird, 2010). This potential biphasic role of
connexins has also been supported in melanoma tumorigenesis due to increasing
evidence that Cx26 facilitates melanoma metastasis (Ito et al., 2000; Saito-Katsuragi et
al., 2007; Stoletov et al., 2013). Uniquely, our model for primary tumor formation in the
chicken embryo also allows for metastasis of tumor cells from the CAM into the
developing embryonic organs, as demonstrated previously (Arpaia et al., 2012; Penuela et
al., 2012; Zijlstra et al., 2002). Although the short duration of the tumor formation assay
in the chicken embryo would not provide sufficient time for the development of
marcometastasis, we can quantitatively assess for micrometastasis in the chicken organs
using a qPCR-based method to detect the mouse Alu repeat sequence, as previously
describe (Zijlstra et al., 2002).

This data would help to further clarify the role of

connexins throughout melanoma tumorigenesis, from primary tumor formation to
metastatic melanoma.
In our studies, we showed that connexin-deficient melanoma cells not only fail to couple
with each other, but also with adjacent keratinocytes in mixed cultures.

Although

melanoma cells have been previously shown to be incapable heterocellular GJIC with
keratinocytes (Hsu et al., 2000a; Hsu et al., 2000b), increasing connexin expression in
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melanoma cells was not previously evaluated as a means to re-establish GJIC with
keratinocytes (Haass and Herlyn, 2005; Hsu et al., 2000a). Interestingly, we showed that
providing melanoma cells with the same connexins as expressed in keratinocytes did not
restore heterocellular GJIC with keratinocytes.

Hsu et al. (2000a) suggested that

cadherins mediate partner-specific binding of connexins. They showed that melanocytes,
which normally express E-cadherin, exhibited GJIC with E-cadherin-expressing
keratinocytes. However, N-cadherin-expressing melanoma cells did not demonstrate
GJIC with keratinocytes, but rather with fibroblasts, which also expressed similar
cadherins and connexins. Additionally, they showed that melanoma cells which retain Ecadherin expression and melanoma cells that were transfected with E-cadherin formed
heterocellular gap junctions with keratinocytes and were capable of dye transfer between
the two cell types. Furthermore, Hsu et al. (2000b) showed that melanoma cells which
expressed E-cadherin display reduced malignancy, perhaps due to this heterocellular
GJIC with keratinocytes. Taken together with our findings, these studies open the door to
an interesting future study to assess the role of connexins and cadherins in melanoma
tumorigenesis. Here, we could assess the tumor suppressive effects of E-cadherin and
Cx43 alone, or in combination. Knowing that Cx43 and E-cadherin each can suppress
melanoma tumorigenesis, it would be interesting to evaluate whether Cx43- and Ecadherin-expressing melanoma cells would display additive or synergistic effects on
reducing tumor growth.
Throughout our studies, we found that both Cx43 and Cx26 were ectopically expressed at
approximately equal levels based on immunoblotting for the GFP tagged added to each
connexin. However, although immunofluorescence images revealed that both Cx26-GFP
and Cx43-GFP trafficked and localized to the cell surface, Cx26-GFP appeared to display
a much more intracellular profile compared to Cx43-GFP. Additionally, although dye
transfer studies revealed that the incidence of dye transfer was statistically similar
between engineered lines and connexin-rich keratinocytes, the degree of dye spread did
not appear to be as robust in melanoma cells expressing Cx26. This may be due to the
intrinsic difference between Cx26-based and Cx43-based channels, however, this may
also be due to the amount of functional gap junctional channels that form in each cell
line. If this is the case, the amount gap junction channels that form in Cx26-expressing
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melanoma cells could, in theory, be significantly less than that obtained in Cx43expressing melanoma cells. Thus we cannot exclude the possibility that a higher degree
of gap junctional-coupling through Cx26 channels may inhibit or promote melanoma
tumorigenesis.
Collectively, our results would strongly suggest that Cx43 acts as a tumor suppressor in
melanoma cells, whereas Cx26 does not significantly change the overall tumorigenic
properties of melanoma cells. These differences may be attributed to the identity of
distinct transjunctional molecules that pass through each respective channel (Alexander
and Goldberg, 2003; Harris, 2007), or potentially due to GJIC-independent mechanisms,
including the interaction with connexin-binding partners to the carboxy-terminus of Cx43
(Laird, 2010; Naus and Laird, 2010). Future studies using mutant connexin proteins or
pharmacological agents may further elucidate the difference between these two general
mechanisms of tumor suppression. Regardless, these studies have clearly identified that
Cx43 is a potent melanoma tumor suppressor, which lends itself to further study as a
future therapeutic target.
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